FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to the field of biotechnology, namely to a conjugate of antibody-drug type, it can be used in medicine. The invention makes it possible to obtain a conjugate of an antibody (or its Fab fragment) to the folic acid alpha receptor with eribulin, an antitumor agent that inhibits the growth phase of microtubules during mitotic cell division. The antibody fragment in the composition of the conjugate according to the present invention contributes to the targeted delivery of a therapeutic agent (eribulin) to the target tumor cells in the patient’s body.
EFFECT: invention can be used as a drug in the treatment of malignant neoplasms which cells overexpress the folic acid receptor, for example, in the treatment of ovarian cancer or tumors of epithelial origin.
44 cl, 23 dwg, 50 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| SCREENING OF ATTACHMENT SITES WITH FIXED POINT IN CYSTEINE-MODIFIED ANTIBODY-TOXIN (TDC) CONJUGATE | 2018 |
|
RU2816510C2 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
